Altered drug metabolism and increased susceptibility to fatty liver disease in a mouse model of myotonic dystrophy.
Animals
Myotonic Dystrophy
/ metabolism
Disease Models, Animal
Mice
Liver
/ metabolism
Humans
Fatty Liver
/ metabolism
Alternative Splicing
Hepatocytes
/ metabolism
Male
Myotonin-Protein Kinase
/ genetics
Mice, Transgenic
Acetyl-CoA Carboxylase
/ metabolism
Female
Mice, Inbred C57BL
Diet, High-Fat
/ adverse effects
Trinucleotide Repeat Expansion
/ genetics
DNA-Binding Proteins
RNA-Binding Proteins
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
04
03
2024
accepted:
10
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
Myotonic Dystrophy type 1 (DM1), a highly prevalent form of muscular dystrophy, is caused by (CTG)
Identifiants
pubmed: 39433769
doi: 10.1038/s41467-024-53378-z
pii: 10.1038/s41467-024-53378-z
doi:
Substances chimiques
Myotonin-Protein Kinase
EC 2.7.11.1
Acetyl-CoA Carboxylase
EC 6.4.1.2
Mbnl1 protein, mouse
0
DMPK protein, mouse
0
DNA-Binding Proteins
0
RNA-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9062Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
ID : R01HL126845
Organisme : U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
ID : R01AA010154
Organisme : Muscular Dystrophy Association (Muscular Dystrophy Association Inc.)
ID : MDA1072487
Informations de copyright
© 2024. The Author(s).
Références
Harper, P. S. Myotonic dystrophy. (W.B. Saunders, London, New York, 2003).
Ashizawa, T. et al. Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol. Clin. Pract. 8, 507–520 (2018).
pubmed: 30588381
pmcid: 6294540
doi: 10.1212/CPJ.0000000000000531
Johnson, N. E. et al. Population-based prevalence of myotonic dystrophy type 1 using genetic analysis of statewide blood screening program. Neurology 96, e1045–e1053 (2021).
pubmed: 33472919
pmcid: 8055332
doi: 10.1212/WNL.0000000000011425
Heatwole, C. et al. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 79, 348–357 (2012).
pubmed: 22786587
pmcid: 3400095
doi: 10.1212/WNL.0b013e318260cbe6
Day, J. W. & Ranum, L. P. W. Genetics and molecular pathogenesis of the myotonic dystrophies. Curr. Neurol. Neurosci. Rep. 5, 55–60 (2005).
pubmed: 15676109
doi: 10.1007/s11910-005-0024-1
Brook, J. D. et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 68, 799–808 (1992).
pubmed: 1310900
doi: 10.1016/0092-8674(92)90154-5
Lee, J. E. & Cooper, T. A. Pathogenic mechanisms of myotonic dystrophy. Biochem. Soc. Trans. 37, 1281–1286 (2009).
pubmed: 19909263
doi: 10.1042/BST0371281
Mankodi, A. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289, 1769–1772 (2000).
Miller, J. W. et al. Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO J 19, 4439–4448 (2002).
doi: 10.1093/emboj/19.17.4439
Jiang, H., Mankodi, A., Swanson, M. S., Moxley, R. T. & Thornton, C. A. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13, 3079–3088 (2004).
pubmed: 15496431
doi: 10.1093/hmg/ddh327
Wang, E. T. et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 150, 710–724 (2012).
pubmed: 22901804
pmcid: 3428802
doi: 10.1016/j.cell.2012.06.041
Lin, X. et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 15, 2087–2097 (2006).
pubmed: 16717059
doi: 10.1093/hmg/ddl132
Chau, A. & Kalsotra, A. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics. Dev. Dyn. 244, 377–390 (2015).
pubmed: 25504326
doi: 10.1002/dvdy.24240
Ho, T. H. et al. Muscleblind proteins regulate alternative splicing. EMBO J. 23, 3103–3112 (2004).
pubmed: 15257297
pmcid: 514918
doi: 10.1038/sj.emboj.7600300
Kalsotra, A. et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc. Natl. Acad. Sci. 105, 20333–20338 (2008).
pubmed: 19075228
pmcid: 2629332
doi: 10.1073/pnas.0809045105
Kalsotra, A. et al. The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression. Cell Rep 6, 336–345 (2014).
pubmed: 24412363
pmcid: 3927417
doi: 10.1016/j.celrep.2013.12.025
Philips, A. V., Timchenko, L. T. & Cooper, T. A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280, 737–741 (1998).
pubmed: 9563950
doi: 10.1126/science.280.5364.737
Yum, K., Wang, E. T. & Kalsotra, A. Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes. Curr. Opin. Genet. Dev. 44, 30–37 (2017).
pubmed: 28213156
pmcid: 5447468
doi: 10.1016/j.gde.2017.01.007
Campbell, N., Brandom, B., Day, J. W. & Moxley, R. Practical suggestions for the anesthetic management of a myotonic dystrophy patient FOREWORD: 1, 1–6 (2010).
Mathieu, J. et al. Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurology 49, 1646 LP–1650 (1997).
doi: 10.1212/WNL.49.6.1646
Bhardwaj, R. R. & Duchini, A. Non-alcoholic steatohepatitis in myotonic dystrophy: DMPK gene mutation, insulin resistance and development of steatohepatitis. Case Rep. Gastroenterol. 4, 100–103 (2010).
pubmed: 21103235
pmcid: 2988905
doi: 10.1159/000292093
Shieh, K., Gilchrist, J. M. & Promrat, K. Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy. Muscle Nerve 41, 197–201 (2010).
pubmed: 19813185
doi: 10.1002/mus.21484
John Herbick, C. J. Hepatic glycogenosis in a patient with type 1 myotonic dystrophy. J. Liver Dis. Transplant. 02, 2012–2014 (2013).
doi: 10.4172/2325-9612.1000110
Achiron, A. et al. Abnormal liver test results in myotonic dystrophy. J. Clin. Gastroenterol. 26, 292–295 (1998).
pubmed: 9649014
doi: 10.1097/00004836-199806000-00016
Morriss, G. R., Rajapakshe, K., Huang, S., Coarfa, C. & Cooper, T. A. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum. Mol. Genet. 27, 2789–2804 (2018).
pubmed: 29771332
pmcid: 6077786
doi: 10.1093/hmg/ddy192
Dong, J. et al. Elucidation of a universal size-control mechanism in drosophila and mammals. Cell 130, 1120–1133 (2007).
pubmed: 17889654
pmcid: 2666353
doi: 10.1016/j.cell.2007.07.019
Lee, J. et al. Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1. Proc. Natl. Acad. Sci. 116, 8709–8714 (2019).
pubmed: 30975744
pmcid: 6500145
doi: 10.1073/pnas.1820827116
Machuca-Tzili, L., Brook, D. & Hilton-Jones, D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 32, 1–18 (2005).
pubmed: 15770660
doi: 10.1002/mus.20301
Wheeler, T. M. & Thornton, C. A. Myotonic dystrophy: RNA-mediated muscle disease. Curr. Opin. Neurol. 20, 572–576 (2007).
pubmed: 17885447
doi: 10.1097/WCO.0b013e3282ef6064
Scotti, M. M. & Swanson, M. S. RNA mis-splicing in disease. Nat. Rev. Genet. 17, 19–32 (2016).
pubmed: 26593421
doi: 10.1038/nrg.2015.3
Misra, C. et al. Aberrant expression of a non-muscle RBFOX2 isoform triggers cardiac conduction defects in myotonic dystrophy. Dev. Cell 52, 748–763.e6 (2020).
pubmed: 32109384
pmcid: 7098852
doi: 10.1016/j.devcel.2020.01.037
Chembazhi, U. V., Bangru, S., Hernaez, M. & Kalsotra, A. Cellular plasticity balances the metabolic and proliferation dynamics of a regenerating liver. Genome Res. 31, 576–591 (2021).
pubmed: 33649154
pmcid: 8015853
doi: 10.1101/gr.267013.120
Nalavade, R., Griesche, N., Ryan, D. P., Hildebrand, S. & Krauß, S. Mechanisms of RNA-induced toxicity in CAG repeat disorders. Cell Death Amp. Dis. 4, e752–e752 (2013).
doi: 10.1038/cddis.2013.276
Wang, P.-Y., Chang, K.-T., Lin, Y.-M., Kuo, T.-Y. & Wang, G.-S. Ubiquitination of MBNL1 is required for its cytoplasmic localization and function in promoting neurite outgrowth. Cell Rep. 22, 2294–2306 (2018).
pubmed: 29490267
doi: 10.1016/j.celrep.2018.02.025
Gates, D. P., Coonrod, L. A. & Berglund, J. A. Autoregulated Splicing of <em>muscleblind</em>-like 1 (<em>MBNL1</em>) Pre-mRNA *. J. Biol. Chem. 286, 34224–34233 (2011).
pubmed: 21832083
pmcid: 3190765
doi: 10.1074/jbc.M111.236547
Kino, Y. et al. Nuclear localization of MBNL1: splicing-mediated autoregulation and repression of repeat-derived aberrant proteins. Hum. Mol. Genet. 24, 740–756 (2015).
pubmed: 25274774
doi: 10.1093/hmg/ddu492
Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).
pubmed: 19131956
doi: 10.1038/nprot.2008.211
Sobczak, K. et al. Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. Mol. Cell 56, 311–322 (2014).
pubmed: 25263597
pmcid: 4224598
doi: 10.1016/j.molcel.2014.08.027
Wang, E. T. et al. Transcriptome alterations in myotonic dystrophy skeletal muscle and heart. Hum. Mol. Genet. 28, 1312–1321 (2019).
pubmed: 30561649
doi: 10.1093/hmg/ddy432
Kanadia, R. N. et al. A muscleblind knockout model for myotonic dystrophy. Science 302, 1978–1980 (2003).
pubmed: 14671308
doi: 10.1126/science.1088583
Bangru, S. et al. Alternative splicing rewires Hippo signaling pathway in hepatocytes to promote liver regeneration. Nat. Struct. Mol. Biol. 25, 928–939 (2018).
pubmed: 30250226
pmcid: 6173981
doi: 10.1038/s41594-018-0129-2
Nitschke, L., Hu, R.-C., Miller, A. N., Lucas, L. & Cooper, T. A. Alternative splicing mediates the compensatory upregulation of MBNL2 upon MBNL1 loss-of-function. Nucleic Acids Res. 51, gkac1219 (2023).
doi: 10.1093/nar/gkac1219
Rogalska, Z. & Sobczak, K. Sustainable recovery of MBNL activity in autoregulatory feedback loop in myotonic dystrophy. Mol. Ther. Nucleic Acids 30, 438–448 (2022).
pubmed: 36420218
pmcid: 9672890
doi: 10.1016/j.omtn.2022.10.023
Veyckemans, F. & Scholtes, J. L. Myotonic Dystrophies type 1 and 2: anesthetic care. Paediatr. Anaesth. 23, 794–803 (2013).
pubmed: 23384336
doi: 10.1111/pan.12120
Groh, W. J. et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N. Engl. J. Med. 358, 2688–2697 (2008).
pubmed: 18565861
doi: 10.1056/NEJMoa062800
James, L. P., Mayeux, P. R. & Hinson, J. A. Acetaminophen-induced hepatotoxicity. Drug Metab. Dispos. 31, 1499–506 (2003).
Zaher, H. et al. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol. Appl. Pharmacol. 152, 193–199 (1998).
pubmed: 9772215
doi: 10.1006/taap.1998.8501
Mcclain, C. J. Potentiation of acetaminophen hepatotoxicity by alcohol. J. Am. Med. Assoc. 244, 251 (1980).
doi: 10.1001/jama.1980.03310030027020
Senggunprai, L., Yoshinari, K. & Yamazoe, Y. Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans. Drug Metab. Dispos. 37, 1711 LP–1717 (2009).
doi: 10.1124/dmd.109.027441
Gamage, N. et al. Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci. 90, 5–22 (2006).
pubmed: 16322073
doi: 10.1093/toxsci/kfj061
Bao, Y. et al. Alterations of cytochrome P450–mediated drug metabolism during liver repair and regeneration after acetaminophen-induced liver injury in mices. Drug Metab. Dispos. 50, 694–703 (2022).
pubmed: 34348940
pmcid: 9132219
doi: 10.1124/dmd.121.000459
Turner, C. & Hilton-Jones, D. The myotonic dystrophies: diagnosis and management. J. Neurol. Neurosurg. Psychiatry 81, 358–367 (2010).
pubmed: 20176601
doi: 10.1136/jnnp.2008.158261
Savkur, R. S., Philips, A. V. & Cooper, T. A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 29, 40–47 (2001).
pubmed: 11528389
doi: 10.1038/ng704
Escolà-Gil, J. C. et al. The cholesterol content of western diets plays a major role in the paradoxical increase in high-density lipoprotein cholesterol and upregulates the macrophage reverse cholesterol transport pathway. Arterioscler. Thromb. Vasc. Biol. 31, 2493–2499 (2011).
pubmed: 21885848
doi: 10.1161/ATVBAHA.111.236075
Elmgren, A. et al. Acutely reduced locomotor activity is a major contributor to western diet-induced obesity in mice. Am. J. Physiol. Endocrinol. Metab. 294, E251–E260 (2007).
pubmed: 18029443
Millar, J. S., Cromley, D. A., McCoy, M. G., Rader, D. J. & Billheimer, J. T. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J. Lipid Res. 46, 2023–2028 (2005).
pubmed: 15995182
doi: 10.1194/jlr.D500019-JLR200
Manual, P. Serum triglyceride quantification kit. https://www.cellbiolabs.com/sites/default/files/STA-396-serum-triglyceride-quantification-kit-colorimetric.pdf (Colorimetric).
Arif, W. et al. Splicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death. Nat. Commun. 14, 551 (2023).
pubmed: 36759613
pmcid: 9911759
doi: 10.1038/s41467-023-35932-3
Ha, J., Daniel, S., Broyles, S. S. & Kim, K. H. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J. Biol. Chem. 269, 22162–22168 (1994).
pubmed: 7915280
doi: 10.1016/S0021-9258(17)31770-2
Halestrap, A. P. & Denton, R. M. Hormonal regulation of adipose-tissue acetyl-coenzyme A carboxylase by changes in the polymeric state of the enzyme. The role of long-chain fatty acyl-coenzyme A thioesters and citrate. Biochem. J. 142, 365–377 (1974).
pubmed: 4155293
pmcid: 1168288
doi: 10.1042/bj1420365
Hunkeler, M. et al. Structural basis for regulation of human acetyl-CoA carboxylase. Nature 558, 470–474 (2018).
pubmed: 29899443
doi: 10.1038/s41586-018-0201-4
Munday, M. R., Campbell, D. G., Carling, D. & Hardie, D. G. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 175, 331–338 (1988).
pubmed: 2900138
doi: 10.1111/j.1432-1033.1988.tb14201.x
Wei, J. et al. A unified molecular mechanism for the regulation of acetyl-CoA carboxylase by phosphorylation. Cell Discov. 2, 16044 (2016).
pubmed: 27990296
pmcid: 5126230
doi: 10.1038/celldisc.2016.44
Witters, L. A., Kowaloff, E. M. & Avruch, J. Glucagon regulation of protein phosphorylation. Identification of acetyl coenzyme A carboxylase as a substrate. J. Biol. Chem. 254, 245–248 (1979).
pubmed: 33166
doi: 10.1016/S0021-9258(17)37904-8
Davies, S. P., Sim, A. T. R. & Hardie, D. G. Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur. J. Biochem. 187, 183–190 (1990).
pubmed: 1967580
doi: 10.1111/j.1432-1033.1990.tb15293.x
Kong, I. S., López-Casillas, F. & Kim, K. H. Acetyl-CoA carboxylase mRNA species with or without inhibitory coding sequence for Ser-1200 phosphorylation. J. Biol. Chem. 265, 13695–13701 (1990).
pubmed: 1974251
doi: 10.1016/S0021-9258(18)77405-X
Winder, W. W. et al. Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. J. Appl. Physiol. 82, 219–225 (1997).
pubmed: 9029219
doi: 10.1152/jappl.1997.82.1.219
Barber, M., Pooley, L. & Travers, M. Developmental regulation of alternatively spliced acetyl-CoA carboxylase-alpha mRNAs encoding isozymes with or without an eight amino acid domain upstream of the Ser-1200 phosphorylation motif in the mammary gland. J. Mol. Endocrinol. 27, 349–356 (2001).
pubmed: 11719287
doi: 10.1677/jme.0.0270349
Badaoui, B. et al. Goat acetyl-coenzyme A carboxylase α: molecular characterization, polymorphism, and association with milk traits. J. Dairy Sci. 90, 1039–1043 (2007).
pubmed: 17235183
doi: 10.3168/jds.S0022-0302(07)71590-4
Harwood, H. J. J. et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J. Biol. Chem. 278, 37099–37111 (2003).
pubmed: 12842871
doi: 10.1074/jbc.M304481200
Zhang, H., Tweel, B., Li, J. & Tong, L. Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with CP-640186. Structure 12, 1683–1691 (2004).
pubmed: 15341732
doi: 10.1016/j.str.2004.07.009
Du, H. et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat. Struct. Mol. Biol. 17, 187–193 (2010).
pubmed: 20098426
pmcid: 2852634
doi: 10.1038/nsmb.1720
Perna, A. et al. High prevalence and gender-related differences of gastrointestinal manifestations in a cohort of DM1 patients: a perspective, cross-sectional study. Front. Neurol. 11, 394 (2020).
pubmed: 32595582
pmcid: 7303304
doi: 10.3389/fneur.2020.00394
Miele, L. et al. Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1). Dig. Liver Dis. 53, 1451–1457 (2021).
pubmed: 33436321
doi: 10.1016/j.dld.2020.12.010
Tanaka, N. et al. Non-alcoholic fatty liver disease later diagnosed as myotonic dystrophy. World J. Hepatol. 12, 685–692 (2020).
pubmed: 33033573
pmcid: 7522559
doi: 10.4254/wjh.v12.i9.685
Hama, M. et al. Metabolic complications in myotonic dystrophy type 1: a cross-sectional survey using the National Registry of Japan. J. Neurol. Sci. 427, 117511 (2021).
pubmed: 34082146
doi: 10.1016/j.jns.2021.117511
Peter, R. et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3, 566–573 (1990).
pubmed: 2103328
doi: 10.1021/tx00018a012
Spracklin, D. K., Hankins, D. C., Fisher, J. M., Thummel, K. E. & Kharasch, E. D. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J. Pharmacol. Exp. Ther. 281, 400–411 (1997).
pubmed: 9103523
Gupta, N. et al. Myotonic dystrophy: an anaesthetic dilemma. Indian J. Anaesth. 53, 688–691 (2009).
pubmed: 20640098
pmcid: 2900080
Bhate, A. et al. ESRP2 controls an adult splicing programme in hepatocytes to support postnatal liver maturation. Nat. Commun. 6, 8768 (2015).
Konieczny, P., Stepniak-Konieczna, E. & Sobczak, K. MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res. 42, 10873–10887 (2014).
pubmed: 25183524
pmcid: 4176163
doi: 10.1093/nar/gku767
Lee, K.-Y. et al. Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol. Med. 5, 1887–1900 (2013).
pubmed: 24293317
pmcid: 3914532
doi: 10.1002/emmm.201303275
Lee, S. R., Pratt, G. A., Martinez, F. J., Yeo, G. W. & Lykke-Andersen, J. Target discrimination in nonsense-mediated mRNA decay requires Upf1 ATPase activity. Mol. Cell 59, 413–425 (2015).
pubmed: 26253027
pmcid: 4673969
doi: 10.1016/j.molcel.2015.06.036
Sznajder, Ł. J. et al. Mechanistic determinants of MBNL activity. Nucleic Acids Res. 44, gkw915 (2016).
doi: 10.1093/nar/gkw915
Konieczny, P., Stepniak-Konieczna, E. & Sobczak, K. MBNL expression in autoregulatory feedback loops. RNA Biol 15, 1–8 (2018).
pubmed: 28949831
doi: 10.1080/15476286.2017.1384119
Fullerton, M. D. et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19, 1649–1654 (2013).
pubmed: 24185692
pmcid: 4965268
doi: 10.1038/nm.3372
Thampy, K. G. & Wakil, S. J. Regulation of acetyl-coenzyme A carboxylase. I. Purification and properties of two forms of acetyl-coenzyme A carboxylase from rat liver. J. Biol. Chem. 263, 6447–6453 (1988).
pubmed: 2896193
doi: 10.1016/S0021-9258(18)68807-6
Softic, S. et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J. Clin. Invest. 127, 4059–4074 (2017).
pubmed: 28972537
pmcid: 5663363
doi: 10.1172/JCI94585
Mao, J. et al. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc. Natl. Acad. Sci. 103, 8552–8557 (2006).
pubmed: 16717184
pmcid: 1570106
doi: 10.1073/pnas.0603115103
Goedeke, L. et al. Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents. Hepatology 68, 2197–2211 (2018).
pubmed: 29790582
doi: 10.1002/hep.30097
Tamura, Y. O. et al. Selective acetyl-CoA carboxylase 1 inhibitor improves hepatic steatosis and hepatic fibrosis in a preclinical nonalcoholic steatohepatitis model. J. Pharmacol. Exp. Ther. 379, 280–289 (2021).
pubmed: 34535562
doi: 10.1124/jpet.121.000786
Zhang, X.-J., Cai, J. & Li, H. Targeting ACC for NASH resolution. Trends Mol. Med. 28, 5–7 (2022).
pubmed: 34844875
doi: 10.1016/j.molmed.2021.11.002
Zhang, X.-J. et al. A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. Sci. Transl. Med. 13, eabg8116 (2021).
pubmed: 34910548
doi: 10.1126/scitranslmed.abg8116
Bian, H., Liu, Y.-M. & Chen, Z.-N. New avenues for NASH therapy by targeting ACC. Cell Metab. 34, 191–193 (2022).
pubmed: 35108509
doi: 10.1016/j.cmet.2022.01.001
Kim, C.-W. et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab. 26, 576 (2017).
pubmed: 28877461
doi: 10.1016/j.cmet.2017.08.011
Calle, R. A. et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat. Med. 27, 1836–1848 (2021).
pubmed: 34635855
doi: 10.1038/s41591-021-01489-1
Loomba, R. et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology 155, 1463–1473.e6 (2018).
pubmed: 30059671
doi: 10.1053/j.gastro.2018.07.027
Li, W.-C., Ralphs, K. L. & Tosh, D. Isolation and culture of adult mouse hepatocytes. In: Methods in Molecular Biology 185–196. https://doi.org/10.1007/978-1-59745-019-5_13 . (Humana Press, 2010).
Fujii, K., Jaffe, H. & Epstein, S. S. Factors influencing the hexobarbital sleeping time and zoxazolamine paralysis time in mice. Toxicol. Appl. Pharmacol. 13, 431–438 (1968).
pubmed: 5749860
doi: 10.1016/0041-008X(68)90119-1
Mcgill, M. R., Williams, C. D., Xie, Y., Ramachandran, A. & Jaeschke, H. Acetaminophen-induced liver injury in rats and mice: Comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. Toxicol. Appl. Pharmacol. 264, 387–394 (2012).
pubmed: 22980195
pmcid: 3478469
doi: 10.1016/j.taap.2012.08.015
Mossanen, J. & Tacke, F. Acetaminophen-induced acute liver injury in mice. Lab. Anim. 49, 30–6 (2015).
pubmed: 25835736
doi: 10.1177/0023677215570992
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562–578 (2012).
pubmed: 22383036
pmcid: 3334321
doi: 10.1038/nprot.2012.016
Anders, S., Pyl, P. T. & Huber, W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
pubmed: 25260700
doi: 10.1093/bioinformatics/btu638
Shen, S. et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc. Natl. Acad. Sci. USA. 111, E5593–601 (2014).
pubmed: 25480548
pmcid: 4280593
doi: 10.1073/pnas.1419161111
Park, J. W., Jung, S., Rouchka, E. C., Tseng, Y.-T. & Xing, Y. rMAPS: RNA map analysis and plotting server for alternative exon regulation. Nucleic Acids Res. 44, W333–W338 (2016).
pubmed: 27174931
pmcid: 4987942
doi: 10.1093/nar/gkw410
Ha, K. C. H., Blencowe, B. J. & Morris, Q. QAPA: a new method for the systematic analysis of alternative polyadenylation from RNA-seq data. Genome Biol. 19, 45 (2018).
pubmed: 29592814
pmcid: 5874996
doi: 10.1186/s13059-018-1414-4
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417–419 (2017).
pubmed: 28263959
pmcid: 5600148
doi: 10.1038/nmeth.4197
Huang, D. W. et al. DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 35, W169–W175 (2007).
pubmed: 17576678
pmcid: 1933169
doi: 10.1093/nar/gkm415
Bonnot, T., Gillard, M. B. & Nagel, D. H. A simple protocol for informative visualization of enriched gene ontology terms. Bio-Protoc. 9, e3429 (2019).
doi: 10.21769/BioProtoc.3429
Supek, F., Bošnjak, M., Škunca, N. & Šmuc, T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One 6, e21800 (2011).
pubmed: 21789182
pmcid: 3138752
doi: 10.1371/journal.pone.0021800
Kent, W. J. et al. The Human genome browser at UCSC. Genome Res. 12, 996–1006 (2002).
pubmed: 12045153
pmcid: 186604
doi: 10.1101/gr.229102
Benoit-Pilven, C. et al. Complementarity of assembly-first and mapping-first approaches for alternative splicing annotation and differential analysis from RNAseq data. Sci. Rep. 8, 4307 (2018).
pubmed: 29523794
pmcid: 5844962
doi: 10.1038/s41598-018-21770-7
Kamentsky, L. et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 27, 1179–1180 (2011).
pubmed: 21349861
pmcid: 3072555
doi: 10.1093/bioinformatics/btr095
Mcquin, C. et al. CellProfiler 3.0: next-generation image processing for biology. PLOS Biol. 16, e2005970 (2018).